



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

OCT 21 2008

Re: TYKERB  
Docket No.: FDA-2007-E-0229

The Honorable Jon Dudas  
Undersecretary of Commerce for Intellectual Property  
Director of the United States Patent and Trademark Office  
Mail Stop Hatch-Waxman PTE  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 6,713,485, filed by SmithKline Beecham Corporation (doing business as GlaxoSmithKline), under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for TYKERB (lapatinib), the human drug product claimed by the patent.

The total length of the regulatory review period for TYKERB (lapatinib) is 2,260 days. Of this time, 2,078 days occurred during the testing phase and 182 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: January 5, 2001.

FDA has verified the applicant's claim that the date the investigational new drug application became effective was on January 5, 2001.

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: September 13, 2006.

FDA has verified the applicant's claim that the new drug application (NDA) for TYKERB (lapatinib) (NDA 22-059) was initially submitted on September 13, 2006.


3. The date the application was approved: March 13, 2007.

FDA has verified the applicant's claim that NDA 22-059 was approved on March 13, 2007.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Jane A. Axelrad". The signature is fluid and cursive, with the first name "Jane" being the most prominent.

Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

cc: John Lemanowicz  
SmithKline Beecham Corp.  
Corporate Intellectual Property Department  
Five Moore Drive  
Research Triangle Park, NC 27709